Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

The European Innovation Network as a hub for medicines innovation in Europe

The European Innovation Network is working to support the European medical innovation ecosystem by facilitating early dialogue between developers of medicines and regulators, as well as providing a platform for regulators to share information, good practices and expertise.
By
  1. Eleonora Agricola

    1. Italian Medicines Agency (AIFA), Rome, Italy.

  2. Caroline Auriche-Benichou

    1. National Agency for the Safety of Medicines and Health Products (ANSM), Saint-Denis, France.

  3. Helena Baiao

    1. National Authority of Medicines and Health Products (Infarmed), Lisbon, Portugal.

  4. Oriane Blanquie

    1. European Medicines Agency (EMA), Amsterdam, The Netherlands; Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

  5. Teodora Bodea

    1. National Institute of Pharmacy and Nutrition (OGYÉI), Budapest, Hungary.

  6. Tomáš Boráň

    1. State Institute for Drug Control (SUKL CZ), Prague, Czech Republic.

  7. John-Joseph Borg

    1. Malta Medicines Authority, San Gwann, Malta.

  8. Valentina Cordo’

    1. European Medicines Agency (EMA), Amsterdam, The Netherlands.

  9. Maria Di Marzo

    1. Italian Medicines Agency (AIFA), Rome, Italy.

  10. Lars Dmowski Rugholm

    1. Danish Medicines Agency (DKMA), Copenhagen, Denmark.

  11. Falk Ehmann

    1. European Medicines Agency (EMA), Amsterdam, The Netherlands.

  12. Rúna Hauksdóttir Hvannberg

    1. Icelandic Medicines Agency (IMA), Reykjavik, Iceland.

  13. Ralf Herold

    1. European Medicines Agency (EMA), Amsterdam, The Netherlands.

  14. Alar Irs

    1. Estonia State Agency of Medicines (Ravimiamet), Tartu, Estonia.

  15. Simona Jurkovič Mlakar

    1. Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP), Ljubljana, Slovenia.

  16. Robert Klaus

    1. Austrian Agency for Health and Food Safety (AGES), Wien, Austria.

  17. Juha Kolehmainen

    1. Finnish Medicines Agency (FIMEA), Helsinki, Finland.

  18. Christophe Lahorte

    1. Federal Agency for Medicines and Health Products (FAMHP), Brussels, Belgium.

  19. Wiebke Löbker

    1. Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.

  20. Anna Mäkinen Salmi

    1. Swedish Medical Products Agency (MPA), Uppsala, Sweden.

  21. Yoana Nuevo Ordoñez

    1. Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain.

  22. Laurence O’Dwyer

    1. Health Products Regulatory Authority (HPRA), Dublin, Ireland.

  23. Anna Maria Gerdina Pasmooij

    1. Dutch Medicines Evaluation Board (MEB), Utrecht, The Netherlands.

  24. Ingvil Saeterdal

    1. Norwegian Medicines Agency (NoMA), Oslo, Norway.

  25. Bronislava Spakova

    1. State Institute for Drug Control (SUKL SK), Bratislava, Slovakia.

  26. Viktoriia Starokozhko

    1. Dutch Medicines Evaluation Board (MEB), Utrecht, The Netherlands.

  27. Bettina Ziegele

    1. Paul Ehrlich Institute (PEI), Federal Institute for Vaccines and Biomedicines, Langen, Germany.

  28. Katarzyna Zywiec

    1. Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw, Poland.

Access through your institution
Buy or subscribe

Introduction

Access options

Access through your institution

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 23, 405-406 (2024)

doi: https://doi.org/10.1038/d41573-024-00039-x

References

  1. Kallio, M. J. et al. Translating academic drug discovery into clinical development: a survey of the awareness of regulatory support and requirements among stakeholders in Europe. Clin. Pharmacol. Ther. 113, 349–359 (2023).

    Article  PubMed  Google Scholar 

  2. Starokozhko, V. et al. Strengthening regulatory science in academia: STARS, an EU initiative to bridge the translational gap. Drug Discov. Today 26, 283–288 (2021).

    Article  PubMed  Google Scholar 

  3. Starokozhko, V. et al. Strategic recommendations from the STARS project to foster academic drug development. Nat. Rev. Drug Discov. 22, 251–252 (2023).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

The authors declare no competing interests. The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency/agencies or organizations with which the author(s) is/are employed/affiliated.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links